Literature DB >> 18514746

Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults.

Elizabeth Thomas1, Peter J Snyder, Robert H Pietrzak, Colleen E Jackson, Martin Bednar, Paul Maruff.   

Abstract

Scopolamine-induced deficits in cognitive and motor processes have been widely demonstrated in animals and humans, although the role of acetylcholine in working memory is not as well understood. This study examined the role of acetylcholine neurotransmission in visuospatial short term and working memory using the Groton Maze Learning Test (GMLT). The GMLT is a computerized hidden maze learning test that yields measures of component cognitive processes such as spatial memory, working memory, and visuomotor function, as well as their integration in trial-and-error problem solving. Healthy older adults were administered scopolamine (0.3 mg subcutaneous), the acetlycholinesterase inhibitor donepezil (5 mg oral), scopolamine with donepezil, or placebo. Compared to placebo, low-dose scopolamine led to performance deficits on all measures of the GMLT. The greatest scopolamine-induced deficits were observed in errors reflecting working memory processes (e.g., perseverative errors d=-2.98, and rule-break errors d=-2.49) and these impairments remained robust when statistical models accounted for scopolamine-related slowing in visuomotor speed. Co-administration of donepezil partially ameliorated scopolamine-related impairments and this effect was greatest for measures of working memory than short-term memory. By itself, donepezil was associated with a small improvement in visuomotor function. These results suggest that scopolamine disrupts processes required for rule maintenance and performance monitoring, in combination with visuomotor slowing and sequential location learning.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514746     DOI: 10.1016/j.neuropsychologia.2008.04.010

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  24 in total

1.  Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: evidence from fMRI in healthy subjects.

Authors:  Bianca Voss; Renate Thienel; Martina Reske; Thilo Kellermann; Abigail J Sheldrick; Sarah Halfter; Katrin Radenbach; Nadim J Shah; Ute Habel; Tilo T J Kircher
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-10-18       Impact factor: 5.270

2.  Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

Authors:  Anushka V Goonawardena; Lianne Robinson; Robert E Hampson; Gernot Riedel
Journal:  Learn Mem       Date:  2010-09-28       Impact factor: 2.460

Review 3.  Short review: Acetylcholinesterase-inhibitors in Alzheimer's disease have opposing effects on blood pressure and cerebral perfusion.

Authors:  J A H R Claassen; A H E A van Beek; M G M Olde Rikkert
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

4.  Hippocampal M1 receptor function associated with spatial learning and memory in aged female rhesus macaques.

Authors:  Gwendolen E Haley; Chris Kroenke; Daniel Schwartz; Steven G Kohama; Henryk F Urbanski; Jacob Raber
Journal:  Age (Dordr)       Date:  2010-10-02

Review 5.  Behavior at the choice point: decision making in hidden pathway maze learning.

Authors:  Elizabeth Thomas; Peter J Snyder; Robert H Pietrzak; Paul Maruff
Journal:  Neuropsychol Rev       Date:  2014-10-28       Impact factor: 7.444

6.  Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Authors:  Ricardo Alvarez-Jimenez; Geert Jan Groeneveld; Joop M A van Gerven; Sebastiaan C Goulooze; Anne Catrien Baakman; Justin L Hay; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2016-07-14       Impact factor: 4.335

7.  Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans.

Authors:  Jan Laczó; Hana Markova; Veronika Lobellova; Ivana Gazova; Martina Parizkova; Jiri Cerman; Tereza Nekovarova; Karel Vales; Sylva Klovrzova; John Harrison; Manfred Windisch; Kamil Vlcek; Jan Svoboda; Jakub Hort; Ales Stuchlik
Journal:  Psychopharmacology (Berl)       Date:  2016-11-24       Impact factor: 4.530

8.  Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans.

Authors:  William Cho; Paul Maruff; John Connell; Cindy Gargano; Nicole Calder; Scott Doran; Sabrina Fox-Bosetti; Aizza Hassan; John Renger; Gary Herman; Christopher Lines; Ajay Verma
Journal:  Psychopharmacology (Berl)       Date:  2011-06-07       Impact factor: 4.530

9.  Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease.

Authors:  Cynthia M Stonnington; Brian Harel; Dona E C Locke; Joseph G Hentz; Nan Zhang; Paul Maruff; Richard J Caselli
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Oct-Dec       Impact factor: 2.703

10.  NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.

Authors:  Samer O Abdul-Hay; Jia Luo; Rezene T Ashghodom; Gregory R J Thatcher
Journal:  J Neurochem       Date:  2009-08-21       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.